Italy: IP And The Pharmaceutical Industry In Italy (Patents And Supplementary Protection)

Last Updated: 5 November 1997
Until recently the pharmaceutical Industry had been complaining of the inadequacy of the Intellectual Property protection available in Italy, and, as far as national industry was concerned, of the negative effect that this was having on its competitiveness with foreign manufacturers, which were granted with a broader protection in their jurisdictions.

It may be useful, in order to understand the present situation and to make a long story short, to briefly summarise the developments occured in the subject matter.

First, it is worth noting that it was not until 1978 that patent protection became available to pharmaceutical products in Italy, when the Constitutional Court pronounced, with its judgment of 20th March 1978, no. 20, the unconstitutionality of art. 14 of r.d. 29th June 1939, no. 1127 (the law on industrial inventions) which prohibited the granting of patents to pharmaceutical inventions, on the ground of some dubious "moral" justifications.

However, despite this important amendment to the law, the pharmaceutical industry found that such reform was inadequate and insufficient. As a matter of fact, while normal patent protection runs for twenty years from the date when the request for patent protection is filed, its manufacturer is immediately able to exploit his product commercially; not so for the producers of pharmaceutical products, who must first obtain authorisation to market their products from the health authorities by means of registration by the Ministry for the Interior in accordance with art. 162 of the unified text of the health laws, no. 1265/1934 as amended by art. 4 of the law no. 422/1941.

Unfortunately, the scientific and technical effort involved in obtaining such authorisation, which is often out of all proportion to the importance of the innovation, leads to long delays before commercialisation is possible. Typically, this leads to delays of up to twelve years from the date of filing the request for patent protection until authorisation is granted so that the actual period which remains for commercial exploitation of the patented product is reduced to eight years.

Thus, with the entering into force of the law of 19th October 1991, no. 349, and the advent of the Supplementary Protection Certificate, a new system of supplementary patent protection was introduced for pharmaceutical products and compounds which are capable of being the object of protection.

It is hardly necessary to say that the idea of the Supplemental Protection Certificate was not an Italian innovation, but one inspired by other legal systems such as those of France, the United States and Japan. The United States and Japan both chose to deal with the problem by introducing the extension of the original period of patent protection.

This approach, however, was not open to Italy or to the other signatories of the Munich and Luxembourg Conventions relating to European and Community patents which established that the twenty year duration of the patent could not be varied by national legislation. It is worth noting here that the European Community also deemed it necessary to introduce Supplementary Protection Certificates for European Patents relating to pharmaceuticals with its Regulation no. 1768/92.

The system of Supplementary Protection Certificates is, however, compatible with the Munich Convention on the European Patent since the Convention does not prevent the signatories from extending patent protection by introducing additional means of protection.

Given the importance of the patent as a method for protecting and nurturing scientific innovation, it is not surprising that the Supplementary Protection Certificates have the same effect (and the same limitations) as the original "base" patent grant.

In Italy, it is possible to request a Supplementary Protection Certificate for Italian patents or for patents having effect in Italy and which relate to pharmaceuticals, use of products as medication and processes for their manufacture.

Turning to the provisions of the Law of no. 349/91, the most significant of the transitional measures are found in article 4 and in accordance with which:

  • requests for grants of patent filed before 18th May 1972 are excluded;
  • owners of pharmaceutical patents who obtained the first ministerial authorisation to market the product before 19th November 1991 and who filed the request for the patent between 18th May 1972 and 13th November 1972 can request a Certificate up to 180 days before the expiry of the patent.
Otherwise, a Certificate may be requested by the owner of the patent within 180 days of the grant of the first ministerial authorisation and, in any event, at least 180 days before the expiry of the patent. In the event that the first authorisation is given before the grant of the patent, a Certificate can be requested within six months of the date of the grant of the patent.

The effect of the Certificate is to extend the duration of the protection for a period equal to the length of time which passes between the date of filing the request for the patent and the date of first authorisation but, in any case, for a maximum period of 18 years.

A Certificate will only be granted on the basis of one patent. In the event that a product is protected by more than one patent, for example, one for the product itself and one for the production process, it is up to the owner of such patents to choose which is to be the "base" patent on which the application for a Certificate will be made. This is particularly important as the protection afforded by the Certificate will be limited to that given by the original patent.

It should also be noted that one product often receives a number of successive authorisations for its commercialisation when, for example, a change is made to its form, to the dosage, to its composition etc. In this case it is the first authorisation that is relevant for the purposes of calculating the time that has passed since the request for the patent was made.

It goes without saying that the "base" patent should be valid and current, as should the authorisation, failing which the Certificate will be void. Care should be taken, since, in the pharmaceutical field, one patent may protect a number of products which conform to the same formula. Of those products, only some will be developed and, eventually, only one will be put on the market. In this case, the Certificate will only protect the product covered by the ministerial authorisation and not the rest of the products covered by the one patent.

In the same way, the protection given by a Certificate to a product which has been authorised will be limited to the subject matter of the "base" patent. Therefore, if an authorised product is made up of more than one active compound, only the compound that is protected by the patent will be protected by the Certificate.

In the event that a party wishes to challenge the validity of the Supplementary Protection Certificate, a request to have a Certificate declared void may be made to the body which first granted it, i.e. to l'Ufficio Italiano Brevetti e Marchi. A Certificate may be declared void for one of the three following reasons:

  • if the conditions for obtaining the Certificate in accordance with art. 4bis of the Law are not fulfilled and, in particular, if the ministerial authorisation is void or was not the first to have been made with respect to that product, or if the "base" patent was no longer valid at the time of requesting a Certificate; or
  • if the "base" patent is void at the date of its legal expiry, or is subsequently declared void. Thus, it is possible to obtain the annulment of the "base" patent after the date for its legal expiry but only in order to obtain annulment of the Certificate; or
  • If the product which is protected by the Certificate is not protected by the "base" patent.
In conclusion, the purpose of the Law no. 349/91 is to extend the length of patent protection actually available to pharmaceutical products, not so that such products enjoy a privileged position, but so that they may enjoy the same length of protection as non-pharmaceutical products and, thus, put an end to the penalising effect that this has had on the Italian pharmaceutical industry with regard to its foreign competitors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions